A Phase II Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of BNC210 in Hospitalised Elderly Patients With Agitation
Phase of Trial: Phase II
Latest Information Update: 02 Oct 2018
At a glance
- Drugs BNC 210 (Primary)
- Indications Agitation
- Focus Therapeutic Use
- Sponsors Bionomics
- 02 Oct 2018 According to a Bionomics media release, data readout is expected Q1, 2019.
- 02 Jun 2018 New trial record
- 24 May 2018 According to a Bionomics media release, this trial has commenced and the first participant has been recruited into the trial.Results of this clinical trial will be available in first quarter of calender year 2019 (Q1, CY2019).